TriangleIvonescimab 10 mg/kg (NCT07057791)
Ivonescimab 10 mg/kg trial for Extensive Stage Lung Small Cell Cancer (NCT07057791). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with extensive-stage small-cell lung cancer who have not received systemic treatment for it and have an ECOG performance score of zero or one.
The idea: ivonescimab targets PD-1 immune suppression and VEGF blood-vessel signals. Random assignment selects 10 or 20 milligrams per kilogram, given intravenously with carboplatin and etoposide for four cycles. Ivonescimab then continues alone every three weeks. Researchers compare tumor responses and serious side effects.
This phase 2 study plans 60 patients. PrECOG sponsors it, with Taofeek Owonikoko as chair; 13 US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.